Roth Capital Issues Negative Forecast for biote Earnings

biote Corp. (NASDAQ:BTMD) – Analysts at Roth Capital lowered their Q4 2024 earnings estimates for biote in a research report issued to clients and investors on Wednesday, November 13th. Roth Capital analyst G. Kelly now expects that the company will post earnings per share of $0.13 for the quarter, down from their prior forecast of $0.19. The consensus estimate for biote’s current full-year earnings is $0.53 per share. Roth Capital also issued estimates for biote’s Q1 2025 earnings at $0.13 EPS, Q2 2025 earnings at $0.16 EPS, Q3 2025 earnings at $0.18 EPS, Q4 2025 earnings at $0.20 EPS and FY2025 earnings at $0.67 EPS.

biote Stock Performance

Shares of BTMD stock opened at $6.57 on Thursday. biote has a fifty-two week low of $3.65 and a fifty-two week high of $8.44. The stock’s fifty day moving average price is $5.53 and its two-hundred day moving average price is $6.28. The company has a market cap of $356.23 million, a PE ratio of 25.85 and a beta of 0.94.

Institutional Trading of biote

Several large investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC bought a new position in biote in the 2nd quarter valued at approximately $42,000. The Manufacturers Life Insurance Company acquired a new stake in shares of biote during the 2nd quarter valued at $84,000. MetLife Investment Management LLC grew its position in biote by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 16,582 shares of the company’s stock worth $93,000 after acquiring an additional 9,343 shares during the last quarter. Victory Capital Management Inc. bought a new position in biote in the third quarter valued at about $106,000. Finally, Bailard Inc. bought a new stake in shares of biote during the second quarter worth about $146,000. 21.68% of the stock is owned by institutional investors and hedge funds.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.